Ticker > Company >

Aarti Drugs share price

Aarti Drugs Ltd.

NSE: AARTIDRUGS BSE: 524348 SECTOR: Pharmaceuticals & Drugs  168k   932   226

416.90
-8.10 (-1.91%)
BSE: 22 Jan 04:01 PM

Price Summary

Today's High

₹ 426.95

Today's Low

₹ 408.2

52 Week High

₹ 634.9

52 Week Low

₹ 414.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

3805.05 Cr.

Enterprise Value

4274.08 Cr.

No. of Shares

9.13 Cr.

P/E

30.43

P/B

3.28

Face Value

₹ 10

Div. Yield

0.24 %

Book Value (TTM)

₹  127.02

CASH

3.82 Cr.

DEBT

472.85 Cr.

Promoter Holding

55.38 %

EPS (TTM)

₹  13.7

Sales Growth

-9.25%

ROE

12.39 %

ROCE

13.7%

Profit Growth

-7.15 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-9.25%
3 Year5.79%
5 Year9.28%

Profit Growth

1 Year-7.15%
3 Year-18.04%
5 Year10.21%

ROE%

1 Year12.39%
3 Year16.11%
5 Year21.38%

ROCE %

1 Year13.7%
3 Year16.63%
5 Year20.91%

Debt/Equity

0.4024

Price to Cash Flow

11.29

Interest Cover Ratio

6.7965

CFO/PAT (5 Yr. Avg.)

1.00673031594346

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2024 55.38 0.00
Sep 2024 55.64 0.00
Jun 2024 55.67 0.00
Mar 2024 57.13 0.00
Dec 2023 57.47 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has a good cash flow management; CFO/PAT stands at 1.00673031594346.
  • The company has a high promoter holding of 55.38%.

 Limitations

  • The company has shown a poor profit growth of -18.0407372739959% for the Past 3 years.
  • The company has shown a poor revenue growth of 5.78643251336355% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 577.54 538.21 559.53 492.96 543.09
Total Expenditure 512.12 478.47 490.47 438.74 483.55
Operating Profit 65.42 59.74 69.06 54.22 59.54
Other Income 0.74 1.68 1.11 0.11 0.38
Interest 7.55 6.75 8.09 7.46 7.17
Depreciation 11.78 11.8 12.34 11.71 11.86
Exceptional Items 0 0 0 0 0
Profit Before Tax 46.83 42.87 49.74 35.16 40.89
Tax 12.25 11.25 13.6 8.25 10.5
Profit After Tax 34.58 31.62 36.14 26.91 30.39
Adjusted EPS (Rs) 3.76 3.44 3.93 2.93 3.33

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1634.92 1914.89 2251.17 2497.97 2266.91
Total Expenditure 1386.98 1510.52 1930.01 2211.92 1997.74
Operating Profit 247.95 404.37 321.17 286.05 269.18
Other Income 1.06 6.42 4.77 2.23 4.18
Interest 35.74 25.71 23.05 36.18 33.21
Depreciation 46.67 47.6 47.39 47.29 47.67
Exceptional Items 8.38 0.22 0 0 0
Profit Before Tax 174.97 337.71 255.5 204.81 192.48
Tax 39.3 80 60.5 52 50.6
Net Profit 135.67 257.71 195 152.81 141.88
Adjusted EPS (Rs.) 14.56 27.65 21.06 16.5 15.43

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 23.3 93.2 92.6 92.6 91.94
Total Reserves 598.49 766.41 879.57 1021.7 1083.27
Borrowings 176.28 147.56 118.33 161.89 238.26
Other N/C liabilities 118.14 107.94 89.34 71.91 73.56
Current liabilities 554.49 521.89 854.68 847.39 684.6
Total Liabilities 1470.7 1637.01 2034.52 2195.5 2171.62
Assets
Net Block 611.57 630.52 649.41 634.48 722.29
Capital WIP 10.96 15.95 59.62 160.75 221.62
Intangible WIP 0 0 0 0 0
Investments 20.38 24.32 28.03 28.62 29.97
Loans & Advances 2.42 6.09 24.26 22.11 16.71
Other N/C Assets 0 0 0 0 0
Current Assets 825.36 960.13 1273.19 1349.53 1181.02
Total Assets 1470.7 1637.01 2034.52 2195.5 2171.62
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 174.97 337.71 255.5 204.81 192.48
Adjustment 79.82 65.35 66.76 78.43 77.69
Changes in Assets & Liabilities -21.34 -161.11 -202.27 -66.71 118.17
Tax Paid -37.32 -87.78 -80.09 -54.83 -51.23
Operating Cash Flow 196.15 154.18 39.9 161.7 337.1
Investing Cash Flow -29.35 -69.03 -125.36 -131.14 -187.09
Financing Cash Flow -167.76 -85.28 84.11 -30.54 -148.81
Net Cash Flow -0.96 -0.13 -1.35 0.03 1.2

Corporate Actions

Investors Details

PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
promoters 57.47 57.13 55.67 55.64 55.38
aarnav rashesh gogri 0.20 0.20 0.20 0.20 0.20
aarti life science llp 0.01 0.01 0.01 0.01 0.01
aashay rashesh gogri 0.96 0.96 0.96 0.96 0.96
aashyav business trust (a... 1.50 1.50 1.50 1.50 1.50
adhish p. patil 1.24 1.24 1.24 1.24 1.24
alchemie financial servic... 0.04 0.04 0.04 0.04 0.04
alchemie finserv pvt. ltd... 2.21 2.21 2.21 2.21 2.21
anushakti enterprise priv... 2.62 2.62 2.62 2.62 2.62
arati tushar sankhe 0.19 0.19 0.19 0.19 0.19
arti rajendra gogri 0.22 0.22 0.15 0.15 0.15
arun moreshwar patil 0.08 0.08 0.08 0.08 0.08
bhoomi harshit savla 1.09 1.09 1.09 1.09 1.09
chandrakant vallabhaji go... 1.87 1.87 1.87 1.87 1.87
dilesh roadlines pvt ltd 0.54 0.54 0.54 0.54 0.54
gogri finserv pvt. ltd. 3.80 3.80 3.80 3.80 3.80
harshit m. savla (huf) (k... 0.01 0.01 0.01 0.01 0.01
harshit manilal savla 4.74 4.74 4.74 4.74 4.74
hetal gogri gala 3.06 3.06 3.06 3.05 3.05
hriman savla 0.02 0.02 0.02 0.02 0.01
indira madan dedhia 0.22 0.21 0.21 0.21 0.21
jay manilal savla 0.29 0.29 0.28 0.28 0.27
jaya chandrakant gogri 1.71 1.71 1.71 1.71 1.71
jigna hiren shah 0.50 0.50 0.50 0.50 0.50
kalika amit mishra 0.03 0.03 0.03 0.03 0.03
kenisha savla 0.02 0.02 0.02 0.02 0.01
manisha rashesh gogri 0.20 0.20 0.20 0.20 0.20
mirik rajendra gogri 1.31 1.31 0.80 0.80 0.70
orchid family trust (rela... 0.99 0.99 0.99 0.99 0.99
paridhi business trust (s... 0.64 0.64 0.64 0.64 0.64
prakash m. patil (huf) (k... - 0.18 0.18 0.18 0.18
prakash moreshwar patil 9.24 9.24 9.24 9.23 9.23
priti prakash patil 4.40 4.40 4.40 4.40 4.40
rajendra vallabhaji gogri... 0.56 0.52 0.11 0.11 0.11
rashesh chandrakant gogri... 4.65 4.65 4.65 4.64 4.64
renil rajendra gogri 1.54 1.25 0.80 0.80 0.66
safechem enterprises priv... 0.61 0.61 0.61 0.61 0.61
seema harshit savla 3.84 3.84 3.84 3.84 3.84
tulip family trust (gloir... 1.01 1.01 1.01 1.01 1.01
uday moreshwar patil 0.06 0.06 0.06 0.06 0.06
vikas moreshwar patil 0.04 0.04 0.04 0.04 0.04
vishwa harshit savla 1.03 1.03 1.03 1.03 1.03
prakash m. patil (huf) (... 0.18 - - - -
PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
investors 42.53 42.87 44.33 44.36 44.62
dsp small cap fund 5.02 5.02 5.64 5.93 6.45
harit pragji shah 2.67 2.67 2.67 2.67 2.67
icici prudential pharma h... - - - - 1.23
investor education and pr... 0.66 0.66 - 0.67 0.68
jayshree harit shah 1.79 1.79 1.79 1.79 1.78
llp 0.08 0.10 0.08 0.10 0.16
blend fund 2 - - 1.22 1.14 -
investor education and pr... - - 0.66 - -
nikhil parimal desai 1.14 1.12 1.06 - -

Ratings & Research Reports

Company Presentations

Company News

Aarti Drugs inks pact to acquire 26.25% stake in Pro-Zeal Green Power Six 10 Jan, 9:58 AM Aarti Drugs gets EIR from USFDA for Maharashtra API manufacturing facility 24 Dec, 3:44 PM Aarti Drugs’ arm incorporates overseas wholly owned subsidiary 28 Nov, 9:16 AM Aarti Drugs - Quaterly Results 24 Oct, 6:04 PM Aarti Drugs - Quaterly Results 24 Oct, 6:04 PM Aarti Drugs gets GMP certificate from UK MHRA 4 Oct, 11:00 AM USFDA completes inspection at Aarti Drugs’ API manufacturing facility 21 Sep, 10:08 AM USFDA issues EIR to Baddi facility of Aarti Drugs’ arm 30 Jul, 11:41 AM Aarti Drugs - Quaterly Results 26 Jul, 5:29 PM Aarti Drugs - Quaterly Results 26 Jul, 5:29 PM Aarti Drugs - Quaterly Results 26 Jul, 5:29 PM Aarti Drugs informs about conference call 19 Jul, 3:38 PM Aarti Drugs informs about compliances-certificate 10 Jul, 5:18 PM Aarti Drugs - Quaterly Results 3 May, 4:30 PM Aarti Drugs - Quaterly Results 3 May, 4:30 PM Aarti Drugs - Quaterly Results 3 May, 4:30 PM USFDA completes inspection at Baddi facility of Aarti Drugs’ arm 23 Apr, 12:47 PM Aarti Drugs - Quaterly Results 24 Jan, 4:02 PM Aarti Drugs - Quaterly Results 24 Jan, 4:02 PM Aarti Drugs - Quaterly Results 24 Jan, 4:02 PM Aarti Drugs - Quaterly Results 19 Oct, 4:00 PM Aarti Drugs - Quaterly Results 19 Oct, 4:00 PM Aarti Drugs - Quaterly Results 19 Oct, 4:00 PM Aarti Drugs informs about newspaper clipping 28 Aug, 3:20 PM Aarti Drugs - Quaterly Results 21 Jul, 4:42 PM Aarti Drugs - Quaterly Results 21 Jul, 4:42 PM Aarti Drugs - Quaterly Results 21 Jul, 4:42 PM Aarti Drugs wins Pharmexcil Outstanding Exports Awards 2021-22 7 Jul, 12:22 PM Aarti Drugs informs about disclosure 2 May, 2:58 PM Aarti Drugs - Quaterly Results 29 Apr, 6:50 PM Aarti Drugs - Quaterly Results 29 Apr, 6:50 PM Aarti Drugs informs about analyst meet 28 Feb, 4:43 PM Aarti Drugs informs about loss of share certificate 25 Feb, 10:53 AM Aarti Drugs - Quaterly Results 27 Jan, 4:43 PM Aarti Drugs - Quaterly Results 27 Jan, 4:43 PM Aarti Drugs - Quaterly Results 27 Jan, 4:43 PM Aarti Drugs informs about disclosure 27 Dec, 2:52 PM Aarti Drugs informs about loss of share certificates 28 Nov, 4:34 PM Aarti Drugs - Quaterly Results 20 Oct, 3:35 PM Aarti Drugs - Quaterly Results 20 Oct, 3:35 PM Aarti Drugs - Quaterly Results 20 Oct, 3:35 PM Aarti Drugs informs about loss of share certificate 20 Aug, 9:44 AM Aarti Drugs informs about scrutinizer's report & voting results of the AGM 5 Aug, 4:20 PM Aarti Drugs informs about proceedings of AGM 5 Aug, 9:46 AM Aarti Drugs - Quaterly Results 27 Jul, 3:55 PM Aarti Drugs - Quaterly Results 27 Jul, 3:55 PM Aarti Drugs - Quaterly Results 27 Jul, 3:55 PM Aarti Drugs informs about board meeting 21 Jul, 9:42 AM Aarti Drugs informs about loss of share certificate 14 Jun, 4:56 PM Aarti Drugs - Quaterly Results 9 May, 3:42 PM

Aarti Drugs Stock Price Analysis and Quick Research Report. Is Aarti Drugs an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Aarti Drugs and its performance over the period of time. Aarti Drugs stock price today is Rs 416.25.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Aarti Drugs cash from the operating activity was Rs 337.1041 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Aarti Drugs has a Debt to Equity ratio of 0.4024 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Aarti Drugs , the EPS growth was -6.4803 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Aarti Drugs has OPM of 11.8741252966481 % which is a bad sign for profitability.
     
  • ROE: Aarti Drugs have a average ROE of 12.3941 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Aarti Drugs is Rs 416.25. One can use valuation calculators of ticker to know if Aarti Drugs share price is undervalued or overvalued.
Last Updated on:
Brief about Aarti Drugs
X